Insilico Fast-Tracks First AI-Designed TNIK Inhibitor For IPF

New Results Released In IPO Filing

InSilico will leapfrog Phase IIb to progress its AI-generated candidate for idiopathic pulmonary fibrosis directly into a Phase III trial in China, as it prepares for an IPO in Hong Kong.

Racetrack — InSilico racing against global competitors for disease-modifying therapy for idiopathic pulmonary fibrosis. • Source: Shutterstock

Artificial intelligence (AI)-driven drug discovery company Insilico Medicine is fast-tracking its first-in-class small molecule targeting Traf2- and Nck-interacting kinase (TNIK) into a Phase III study in China for idiopathic pulmonary fibrosis (IPF).

Another Phase IIb/III study in the US for the asset, rentosertib (ISM001-055), designed using generative AI, is also planned, the...